Anna Silenzi, DO
Cardiovascular Disease · Kenosha, WINPI 1639365661
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,404 of the $3,891 with a category attached, or 87.5%. It is spread thinly across 27 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,249, more than ten times the $16 reported in 2020.
Across 160 payments — averaging $24.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$713
- GE HealthCare$398
- Novo Nordisk$395
- Novartis$333
- Amgen$298
- Johnson & Johnson$257
- plus $1K from 21 others
What the payments were for
- Consulting fees$39810%
- Food & beverage$3,40487%
- Education$892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 42 | $713 |
| GE HealthCare | 1 | $398 |
| Novo Nordisk | 13 | $395 |
| Novartis | 15 | $333 |
| Amgen | 15 | $298 |
| Johnson & Johnson | 14 | $257 |
| Heartflow, Inc. | 12 | $256 |
| Pfizer | 10 | $197 |
| Actelion Pharmaceuticals US, Inc. | 2 | $188 |
| AstraZeneca | 5 | $178 |
| Abiomed | 5 | $101 |
| Biotronik Inc. | 1 | $91 |
| Lexicon Pharmaceuticals, Inc. | 4 | $81 |
| Recor Medical Inc | 4 | $79 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $63 |
| Abbott | 2 | $47 |
| Philips North America LLC | 1 | $33 |
| Veryan Medical Incorporated | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Livanova USA, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Inari Medical, Inc. | 1 | $19 |
| Merck | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Chiesi USA, Inc. | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,891 in reported general payments places this provider in the 75th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 433 | $544,524 |
| VyndamaxTafamidis | 12 | $264,528 |
| XareltoRivaroxaban | 95 | $129,686 |
| EntrestoSacubitril/Valsartan | 62 | $80,021 |
| JardianceEmpagliflozin | 37 | $40,833 |
| Repatha SureclickEvolocumab | 25 | $35,456 |
| BrilintaTicagrelor | 21 | $18,937 |
| FarxigaDapagliflozin Propanediol | 13 | $13,936 |
| Amiodarone Hcl | 223 | $8,421 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $7,559 |
| Potassium Chloride | 126 | $4,880 |
| ClopidogrelClopidogrel Bisulfate | 412 | $4,541 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 121 | $4,429 |
| Metoprolol Succinate | 366 | $4,196 |
| Digoxin | 129 | $3,910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $197 | $809,051445 claims |
| Johnson & JohnsonXarelto | $257 | $129,68695 claims |
| NovartisEntresto | $333 | $80,02162 claims |
| Boehringer IngelheimJardiance | $20 | $40,83337 claims |
| AstraZenecaBrilinta, Farxiga | $178 | $32,87334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 322 cardiovascular disease providers in Wisconsin.
Other cardiovascular disease in Kenosha
- Subhashish AgarwalBrookfield$378K
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
- Joshua LibermanMequon$230K
- Imdad AhmedJanesville$164K
- David MurdockWausau$164K
- Eric RobertsMilwaukee$131K
- Renuka JainMilwaukee$131K
- Evgenia RaichlinMilwaukee$73K
- Tadeo Diaz BalderramaFond du Lac$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.